Swedish Orphan Biovitrum AB (publ)
BIOVFOTCHealthcare● Active
$47.35
$-0.13(-0.26%)
Market Cap$16.4B
P/E Ratio—
52W High$48
52W Low$27.06
Swedish Orphan Biovitrum AB (publ) (BIOVF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BIOVF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 28, 2026EPS Actual
$0.45
Est. $0.38 · +17.8%
Revenue
$0.76B
Est. $0.75B · +0.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 28, 2026
After Market Close
▲ Beat EPS🔥 7-Quarter EPS Beat Streak
BIOVF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 16, 2026 | $0.38 | — | — | — | $0.77B | — |
| ▲ Q2 FY2026 | Apr 28, 2026 | $0.38 | $0.45 | +17.8% | $0.76B | $0.75B | +0.8% |
| ▲ Q1 FY2026 | Feb 5, 2026 | $0.46 | $0.60 | +31.4% | $0.85B | $0.86B | -2.0% |
| ▲ Q4 FY2025 | Oct 20, 2025 | $0.49 | $0.64 | +29.9% | $0.82B | $0.88B | -6.0% |
| ▲ Q3 FY2025 | Jul 16, 2025 | $0.18 | $0.24 | +35.6% | $0.65B | $0.81B | -20.7% |
| ▲ Q2 FY2025 | Apr 29, 2025 | $0.22 | $0.26 | +20.8% | $0.65B | $0.65B | -0.0% |
| ▲ Q1 FY2025 | Feb 5, 2025 | $0.32 | $0.37 | +14.4% | $0.67B | $0.56B | +19.1% |
| ▲ Q4 FY2024 | Oct 24, 2024 | $0.22 | $0.40 | +84.8% | $0.66B | $0.59B | +12.4% |
Q3 FY2026
Jul 16, 2026
EPS Actual
—
EPS Est.
$0.38
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 28, 2026Beat
EPS Actual
$0.45
EPS Est.
$0.38
EPS Surpr.
+17.8%
Revenue
$0.76B
Q1 FY2026
Feb 5, 2026Beat
EPS Actual
$0.60
EPS Est.
$0.46
EPS Surpr.
+31.4%
Revenue
$0.85B
Q4 FY2025
Oct 20, 2025Beat
EPS Actual
$0.64
EPS Est.
$0.49
EPS Surpr.
+29.9%
Revenue
$0.82B
Q3 FY2025
Jul 16, 2025Beat
EPS Actual
$0.24
EPS Est.
$0.18
EPS Surpr.
+35.6%
Revenue
$0.65B
Q2 FY2025
Apr 29, 2025Beat
EPS Actual
$0.26
EPS Est.
$0.22
EPS Surpr.
+20.8%
Revenue
$0.65B
Q1 FY2025
Feb 5, 2025Beat
EPS Actual
$0.37
EPS Est.
$0.32
EPS Surpr.
+14.4%
Revenue
$0.67B
Q4 FY2024
Oct 24, 2024Beat
EPS Actual
$0.40
EPS Est.
$0.22
EPS Surpr.
+84.8%
Revenue
$0.66B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $9.73 | $9.98 | $10.23 | 1 |
| Q3 FY2027 | $9.86 | $10.11 | $10.37 | 1 |
| Q2 FY2027 | $6.02 | $6.18 | $6.33 | 1 |
| Q1 FY2027 | $6.26 | $6.42 | $6.58 | 1 |
| Q4 FY2026 | $5.22 | $5.36 | $5.49 | 1 |
| Q3 FY2026 | $5.85 | $6.00 | $6.15 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $10.8B | $11.0B | $11.2B | 1 |
| Q3 FY2027 | $10.5B | $10.7B | $10.9B | 1 |
| Q2 FY2027 | $8.6B | $8.8B | $9.0B | 1 |
| Q1 FY2027 | $8.4B | $8.6B | $8.8B | 1 |
| Q4 FY2026 | $8.8B | $9.0B | $9.1B | 1 |
| Q3 FY2026 | $8.6B | $8.7B | $8.9B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 28, 2026 | +17.8% | $43.15 | $43.15 | +0.00% |
| ▲ Q1 FY2026 | Feb 5, 2026 | +31.4% | $37.00 | $37.00 | +0.00% |
| ▲ Q4 FY2025 | Oct 20, 2025 | +29.9% | $33.30 | $33.30 | +0.00% |
| ▲ Q3 FY2025 | Jul 16, 2025 | +35.6% | $29.25 | $29.79 | +1.85% |
| ▲ Q2 FY2025 | Apr 29, 2025 | +20.8% | $29.00 | $29.00 | +0.00% |
| ▲ Q1 FY2025 | Feb 5, 2025 | +14.4% | $30.48 | $30.48 | +0.00% |
| ▲ Q4 FY2024 | Oct 24, 2024 | +84.8% | $29.50 | $31.50 | +6.78% |
| ▼ Q3 FY2024 | Jul 16, 2024 | -2.5% | No price data | $25.20 | — |
Q2 FY2026+0.00%
Report Date
Apr 28, 2026
EPS Beat/Miss
+17.8%
Price Before
$43.15
Price After
$43.15
Q1 FY2026+0.00%
Report Date
Feb 5, 2026
EPS Beat/Miss
+31.4%
Price Before
$37.00
Price After
$37.00
Q4 FY2025+0.00%
Report Date
Oct 20, 2025
EPS Beat/Miss
+29.9%
Price Before
$33.30
Price After
$33.30
Q3 FY2025+1.85%
Report Date
Jul 16, 2025
EPS Beat/Miss
+35.6%
Price Before
$29.25
Price After
$29.79
Q2 FY2025+0.00%
Report Date
Apr 29, 2025
EPS Beat/Miss
+20.8%
Price Before
$29.00
Price After
$29.00
Q1 FY2025+0.00%
Report Date
Feb 5, 2025
EPS Beat/Miss
+14.4%
Price Before
$30.48
Price After
$30.48
Q4 FY2024+6.78%
Report Date
Oct 24, 2024
EPS Beat/Miss
+84.8%
Price Before
$29.50
Price After
$31.50
Q3 FY2024—
Report Date
Jul 16, 2024
EPS Beat/Miss
-2.5%
Price Before
—
Price After
$25.20
Avg Beat Reaction+1.23%
Beat Rate7 / 8 quarters
Largest Move+6.78% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BIOVF ends December
Swedish Orphan Biovitrum AB (publ) (BIOVF) most recently reported earnings on April 28, 2026 for Q2 FY2026, posting EPS of $0.45 — beating the analyst consensus of $0.38 by +17.8%. BIOVF has beaten EPS estimates for 7 consecutive quarters. The next BIOVF earnings date is expected around September 1, 2026.
Each quarter, investors track BIOVF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BIOVF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BIOVF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BIOVF earnings · 5 questionsSwedish Orphan Biovitrum AB (publ)'s next earnings report is expected around September 1, 2026. BIOVF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BIOVF historically reports after market close (AMC).
BIOVF earnings datewhen is BIOVF earningsBIOVF next earnings datewhen does BIOVF report earningsBIOVF earnings calendar
▸ Source: FMP · Swedish Orphan Biovitrum AB (publ) SEC filings · US GAAP · Swedish Orphan Biovitrum AB (publ) SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026